Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. - Wikidata - wikimedia - TriplyDB

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

http://www.wikidata.org/entity/Q33393436

about

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Bortezomib for the treatment of mantle cell lymphoma: an update The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Next-generation prognostic assessment for diffuse large B-cell lymphoma New molecular targets in mantle cell lymphoma How I treat HIV-associated lymphoma Constitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis Treatment of diffuse large B cell lymphoma Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Trial Watch: Proteasomal inhibitors for anticancer therapy Current and emerging therapies in mantle cell lymphoma.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.My treatment approach to patients with diffuse large B-cell lymphoma.Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.EBV-positive diffuse large B-cell lymphoma of the elderly Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Molecular targeted approaches in mantle cell lymphoma.Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile.Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations.The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside Proteasome inhibitors in mantle cell lymphoma Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

P2860

Q24597424-78C7CA4E-EA0A-48BB-B6DF-192563E80899 Q26738940-479C877F-175C-4E43-A7DA-2E7E21A3E444 Q26772907-8B3017BE-BF79-4466-96E4-924FE97ED4A8 Q26796428-0FAC1B82-5931-40AF-9650-E03BF9665CC2 Q26821766-ACFDE6CF-F2D4-402A-895E-08C7E7799E1E Q26821860-E8BADC67-C9E6-429C-B943-4F077AE81E1A Q26853170-9D24D634-C2CC-47F1-9DF2-1BD24E461C60 Q26991817-B8832F2F-2A97-48B2-8E3C-BDC81D6F0D50 Q27006062-C15B0596-F613-4FCB-B1E8-1AF699627800 Q27027137-F0D56654-6CCD-4F4B-BAF9-1F615C484DA7 Q27304386-AF9CA8DE-AE7F-44B7-8512-3E22E1CFACE5 Q28075606-D4A891CE-9B72-4D07-80F2-5E4940E5B3D2 Q28082910-74084DEA-5C72-4151-9D48-7F28EA96EF5A Q30456545-5AF950E9-0448-46ED-AB2F-2A1133E5F525 Q33404090-70859FA6-2018-41FB-B10D-CFF7FB0C6BAD Q33416533-4B7A1077-133C-4CAC-B57C-CB472D2A8E2D Q33418257-30E4BFE9-05BA-4F5B-AEA2-7947533F714B Q33424956-E3A2CC7A-5DE2-421E-8DE6-3EF3C69256FB Q33583294-325B9C1F-BE2A-4A67-930F-62003A257898 Q33586239-D69461D2-76CA-412A-9833-756CFF784E09 Q33761796-36947A9B-EF6D-475A-8B1D-49C3E0734BF1 Q33889168-A55FE849-AE58-4B2C-892B-D5D390AC241A Q34251964-32D0ED96-87DB-4C7C-AD9F-DE9905832BC2 Q34332888-656F0037-1186-4253-9749-4D3D3C57DF5A Q34343242-B0563943-002B-402D-9A48-639B14A79B16 Q34405616-7E58097F-9909-45A6-9D6A-D9769B7CA70F Q34617849-B21A1551-CF72-424D-AF92-810EC884CE4D Q34646755-7636E4B0-D0B5-46BE-8641-CDA709A8471C Q34788381-2B858DDA-6355-4C84-9C7C-6D8C10866D53 Q34882773-433B8E71-8570-4143-AC67-53BC8160DAAE Q35127368-00C64211-746A-4381-B299-7E2F5F8C63C4 Q35247997-BAAA69BF-68BD-41C4-A8B5-11F81927F21B Q35419876-C0B72118-8B53-406C-922A-AB6EABF86FE9 Q35475256-9BEBCA8F-F9D3-4A5D-8F06-D79953AE8C21 Q35493964-D5AB2488-F034-4351-B489-857ACB4C4142 Q35607281-3749F86A-5449-443D-84A7-08F57C2907A5 Q35989980-E613DDF3-D3B4-48BA-BE5C-7A5B9C71F30B Q36028745-C386B9D4-2872-4A2F-B513-8EF372C52FF1 Q36192439-1C7A8493-386E-403C-AB25-3F22C023D716 Q36278006-E8681C41-B2B9-449D-91A1-D38E98CB74A1

P2860

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

http://www.wikidata.org/entity/Q33393436

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Bortezomib plus CHOP-rituximab ...... homa and mantle cell lymphoma.

@ast

Bortezomib plus CHOP-rituximab ...... homa and mantle cell lymphoma.

@en

type

label

Bortezomib plus CHOP-rituximab ...... homa and mantle cell lymphoma.

@ast

Bortezomib plus CHOP-rituximab ...... homa and mantle cell lymphoma.

@en

prefLabel

Bortezomib plus CHOP-rituximab ...... homa and mantle cell lymphoma.

@ast

Bortezomib plus CHOP-rituximab ...... homa and mantle cell lymphoma.

@en

P1433

Q33393436-3243CA24-21B7-4E96-89AD-D71E5C5FE263

P1476

Q33393436-1B54FDF8-8E69-492A-A396-30540195FA59

P2093

Q33393436-05484A00-272E-4F4D-8882-5B1243EAC259

Q33393436-0C75C33E-B3CF-4280-9D37-999DB29A3C78

Q33393436-1B137E61-5420-442D-81FB-30EA4B31EA82

Q33393436-38347C13-3FC3-443C-BBF5-BDD3AD000231

Q33393436-460050BB-A5BE-4C81-BFE7-EEB00C9CCA12

Q33393436-676A788D-B8A6-42D8-9B77-BEE43EF75A48

Q33393436-8647A8B7-E64D-4D86-8367-E34C369A2D50

Q33393436-8CAAAC51-122C-4116-A936-467FA353A342

Q33393436-93F872B6-CDD4-4E05-8945-3F4F7F8601D8

Q33393436-945AD851-4C93-4372-AB38-34B9EB91149F

P304

Q33393436-F0F2DC8B-A611-40E3-9EED-C006442AF34A

P31

Q33393436-3A9259F6-CC69-4608-966D-11EEB510D827

P356

Q33393436-57CC0C17-07CB-4CA8-B0D4-994C7EA147A8

P407

Q33393436-BAD1FC99-65D4-4D11-B730-B752CCAFC329

P433

Q33393436-1A814128-3B06-4738-B709-9D63923FA0F5

P478

Q33393436-1FDC91CB-768E-4E8B-A392-E4E847EC5267

P50

Q33393436-D3C50E41-2344-4C98-B0B3-823DCDE17939

P577

Q33393436-94DC15EC-0D0A-4284-9FEB-0EC8B04AC065

P698

Q33393436-94EB069E-2F78-4336-BF37-C32E6900EEA4

P356

JCO.2010.31.1142

P1433

Journal of Clinical Oncology

P1476

Bortezomib plus CHOP-rituximab ...... homa and mantle cell lymphoma.

@en

P2093

Amy Chadburn

http://www.w3.org/2001/XMLSchema#string

Ann Lacasce

http://www.w3.org/2001/XMLSchema#string

Ethel Cesarman

http://www.w3.org/2001/XMLSchema#string

Jia Ruan

http://www.w3.org/2001/XMLSchema#string

John P Leonard

http://www.w3.org/2001/XMLSchema#string

Julia Morrison

http://www.w3.org/2001/XMLSchema#string

Ken Cheung

http://www.w3.org/2001/XMLSchema#string

Morton Coleman

http://www.w3.org/2001/XMLSchema#string

Peter Martin

http://www.w3.org/2001/XMLSchema#string

Rebecca Elstrom

http://www.w3.org/2001/XMLSchema#string

P304

690-697

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.31.1142

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21189393

http://www.w3.org/2001/XMLSchema#string